Browse Studies — Arctuva

Phase 1

A Phase 1 Study of ZEN003694 (ZEN-3694) in Combination With Cetuximab and Encorafenib in Patients With Refractory BRAF V600E Metastatic Colorectal Cancer

This phase I trial tests the safety, best dose, and effectiveness of ZEN003694 in combination with cetuximab and encorafenib in treating patients with colorect…

Metastatic Colorectal AdenocarcinomaRecurrent Colorectal AdenocarcinomaRefractory Colorectal Adenocarcinoma+1 more

Estimated

~$150 – $2,700

Actual pay is set by the research site.